SHARE
ASCO GU 2021: Association of Reductions in PSA Screening Across States with Increased Metastatic Prostate Cancer in the United States
Published 13 February 2021
(UroToday.com) Prostate cancer screening using prostate-specific antigen (PSA) testing has been controversial since shortly after its introduction in large part due to concerns of over-diagnosis and over-treatment, with the associated morbidity. Thus, despite improvements in prostate cancer-related metastasis and mortality demonstrated in the European Randomized Study of Screening for Prostate Cancer (ERSPC) randomized trial from Europe, PSA screening has remained contentious. In both 2008 and 2012, the US Preventive Services Task Force (USPSTF) did not recommend PSA screening. Some have attributed increased rates of metastatic prostate cancer in the US to reductions in PSA screening as a result of these recommendations from the USPSTF. To test this hypothesis, in the Poster Highlights: Prostate Cancer - Localized
SHARE
ASCO GU 2021: Alignment and Discordances in Perceptions and Experiences of Shared Decision Making Among Bladder Cancer Patients and Their Care Team
Published 13 February 2021
(UroToday.com) Shared decision-making regarding cancer treatment is critical. In previous PRIME educational programs involving patients with bladder cancer and their care teams, effective shared decision-making was found to be integral to the development of treatment plans that reflected patient preferences and treatment goals. However, oncology care teams face complex barriers that impede their ability to personalize bladder cancer therapy for each patient. PRIME conducted a Collaborative Learning Program in five US healthcare systems to support communication and shared decision-making between patients with bladder cancer and their urology/medical oncology teams to improve outcomes and quality of life for these patients. At the 2021 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Ca
KEYTRUDA Plus LENVIMA Significantly Reduced Risk of Disease Progression or Death by 61% Versus Sunitinib, With a Median PFS of Nearly Two Years Versus Nine Months for Sunitinib LENVIMA Plus Everolimus Significantly Improved PFS and Objective Response Rate Versus Sunitinib First Results From Pivotal CLEAR Study Presented at 2021 Genitourinary Cancers Symposium and Published in the New England Journal of Medicine … KEYTRUDA Plus LENVIMA Significantly Reduced Risk of Disease Progression or Death by 61% Versus Sunitinib, With a Median PFS of Nearly Two Years Versus Nine Months for Sunitinib LENVIMA Plus Everolimus Significantly Improved PFS and Objective Response Rate Versus Sunitinib First Results From Pivotal CLEAR Study (KEYNOTE-581/Study 307) Presented at 2021 Genitourinary Cancers Symposium (ASCO GU) and Published in the New England Journal of Medicine
Androgen Annihilation Strategy Prolongs rPFS in mCRPC medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Combo Disappoints in Metastatic Prostate Cancer medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.